Related Experiment Video

Updated: May 23, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Epigenetic aspects on therapy development for gastroenteropancreatic neuroendocrine tumors

Catharina Larsson1

  • 1Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. Catharina.Larsson@ki.se

Neuroendocrinology
|March 30, 2012
PubMed

Insights

Epigenetic modifications are crucial in gastroenteropancreatic neuroendocrine tumors. Targeting these alterations with drugs like azacytidine and histone deacetylase inhibitors shows promise for novel cancer therapies.

Area of Science:

  • Oncology
  • Epigenetics
  • Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Background:

  • Epigenetic modifications are under investigation in GEP-NETs.
  • Loss of imprinting at the insulin-like growth factor 2 gene locus is a known epigenetic alteration in insulinoma.
  • MEN1 gene inactivation impacts histone methylation in pancreatic tumors.

Purpose of the Study:

  • To explore the role of epigenetic modifications in GEP-NETs.
  • To review current understanding and potential therapeutic targets.
  • To highlight the need for complementary treatments beyond surgery.

Main Methods:

  • Review of existing literature on epigenetic alterations in GEP-NETs.
  • Analysis of the impact of gene mutations (MEN1) on epigenetic mechanisms.
  • Evaluation of in vitro studies on epigenetic drug effects.

Main Results:

  • Activation of the IGF2 gene locus via loss of imprinting is common in insulinoma.
  • MEN1 inactivation affects histone H3K4me3 methylation.
  • Inhibitors of DNA methyltransferase (e.g., azacytidine) and histone deacetylation (e.g., butyrate, valproic acid) show promising in vitro effects on tumor phenotypes.

Conclusions:

  • Epigenetic alterations are significant in GEP-NETs.
  • Pharmacological targeting of epigenetic mechanisms offers potential therapeutic strategies.
  • Further research and drug development are warranted for GEP-NET treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...